

Reprint Fulfillment

The *Journal of Clinical Oncology* published the pivotal phase 2b trial results for ReNeu; this study evaluated the use of mirdametinib, an investigational product being studied in adults and children with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN).

The citation for this publication is: Moertel CL, Hirbe AC, Shuhaiber HH, et al. ReNeu: a pivotal, phase IIb trial of mirdametinib in adults and children with symptomatic plexiform neurofibroma. *J Clin Oncol*. 2024. Epub ahead of print. doi:10.1200/JCO.24.01034.

This article is open access to interested stakeholders and can be downloaded through the [ReNeu Publication hyperlink](#), or through the *Journal of Clinical Oncology*.

Mirdametinib is an investigational agent. It has not been approved by the US Food and Drug Administration (FDA) or any regulatory authority; the safety and efficacy of mirdametinib have not been established.